Narayan, V.; Barber-Rotenberg, J.S.; Jung, I-Y.; Lacey, SF.; Rech, AJ.; Davis, MM.; Hwang, W-T.; Lal, P.; Carpenter, EL.; Maude, SL.; Plesa, G.; Vapiwala, N.; Chew, A.; Moniak, M.; Sebro, RA.; Farwell, MD.; Marshall, A.; Gilmore, J.; Lledo, L.; Dengel, K.; Church, SE.; Hether, TD.; Xu, J.; Gohil, M.; Buckingham, TH.; Yee, SS.; Gonzalez, VE.; Kulikovskaya, I.; Chen, F.; Tian, L.; Tien, K.; Gladney, W.; Nobles, CL.; Raymond, H.; Prostate Cancer Cellular Therapy Program Investigators, Hexner, EO.; Siegel, DL.; Bushman, FD.; June, CH.; Fraietta, JA.; Haas, NB. PSMA-targeting TGFβ-insensitive Armored CAR T-cells in Metastatic Castration Resistant Prostate Cancer: a Phase 1 Trial , Nat Med, 28(4): 2022,724-734
Jonasch, E.; Donskov, F.; Iliopoulos, O.; Rathmell, WK.; Narayan, V.; Maughan, BL.; Oudard, S.; Else, T.; Maranchie, JK.; Welsh, SJ.; Thamake, S.; Park, EK.; Perini, RF.; Linehan, WM.; Srinivasan, R. Belzutifan for Von Hippel-Lindau Disease–Associated Renal Cell Carcinoma , New Engl J Medicine
, 385(22): 2021,2036-2046
Dorff, TB.;* Narayan, V.;* Forman, SJ.; Zang, PD.; Fraietta, JA.; June, CH.; Haas, NB.; Priceman, SJ. Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer , Clin Cancer Res, 28(4): 2021,576-584
Pal, SK.; Tangen, C.; Thompson, IM.; Haas, NB.; George, DJ.; Heng, D.; Shuch, B.; Stein, M.; Tretiakova, M.; Humphrey, P.; Adeniran, A.; Narayan, V.; Bjarnason, G.; Vaishampayan, U.; Alva, A.; Zhang, T.; Cole, S.; Plets, M.; Wright, J.; Lara, P. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial , Lancet, 397(10275): 2021,695-703
Sharma, P.; Pachynski, RK.; Narayan, V.; Fléchon, A.; Gravis, G.; Galsky, M.; Mahammedi, H.; Patnaik, A.; Subudhi, SK.; Ciprotti, M.; Simsek, B.; Saci, A.; Hu, Y.; Han, GC.; Fizazi, K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial , Cancer Cell, 38(4): 2020,489-499
Narayan, V.; Harrison, M.; Cheng, H.; Kenfield, S.; Aggarwal, R.; Kwon, D.; McKay, R.; Hauger, R.; Hart, N.; Conzen, S.; Borno, H.; Jim, H.; Dicker, A.; Dorff, T.; Moslehi, J.; Mucci, L.; Parsons, JK.; Saad, F.; Soule, H.; Morgans, A.; Ryan, CJ. Improving Research for Prostate Cancer Survivorship: A Statement from the SuRECaP (Survivorship Research in Prostate Cancer) Working Group , Urologic Oncology: Seminars and Original Investigations, 38(3): 2020,83-93
Narayan, V.; Puligandla, M.; Haas, NB.; Subramanian, P.; DiPaola, RS.; Uzzo, R. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance for Patients with High-Risk Non-Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial , J Urol, 201(1): 2019,62-68
Narayan, V.; Keefe, S.; Haas, NB.; Wang, L.; Puzanov, I.; Putt, M.; Catino, A.; Fang, J.; Agarwal, N.; Hyman, D.; Smith, AM.; Finkelman, B.; Narayan, HK.; Ewer, S.; ElAmm, C.; Lenihan, D.; Ky, B. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma , Clin Cancer Res, 23(14): 2017,3601-3609
Jung, IY.; Bartoszek, RL.; Rech, AJ.; Collins, SM.; Ooi, SK.; Williams, EF.; Hopkins, CR.; Narayan, V.; Haas, NB.; Frey, NV.; Hexner, EO.; Siegel, DL.; Plesa, G.; Porter, DL.; Cantu, A.; Everett, JK.; Guedan, S.; Berger, SL.; Bushman, FD.; Herbst, F.; Fraietta, JA. Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction , Cancer Discov, 13(7): 2023,1636-1655
Schram, AM.; Colombo, N.; Arrowsmith, E.; Narayan, V.; Yonemori, K.; Scambia, G.; Zelnak, A.; Bauer, TM.; Jin, N.; Ulahannan, SV.; Colleoni, M.; Aftimos, P.; Donoghue, M.; Rosen, E.; Rudneva, V.; Telli, ML.; Domchek, SM.; Galsky, M.; Hoyle, M.; Chappey, C.; Stewart, R.; Blake-Haskins, JA.; Yap, TA. Avelumab Plus Talazoparib in BRCA1/2- or ATM-Altered Advanced Solid Tumors (JAVELIN BRCA/ATM): Results From an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial , JAMA Oncology, 17(1): 2022,e225218
